


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:58:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 93 TO 587

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 09:58:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 322 TO ITERATE

100.0% PROCESSED 322 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.02

L3 13 SEA SSS FUL L1

=> s 13

L4 5 L3

=> DUP REM L4

PROCESSING COMPLETED FOR L4

L5 5 DUP REM L4 (0 DUPLICATES REMOVED)

=> d 14 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:813875 CAPLUS

DOCUMENT NUMBER: 137:329436

TITLE: Prodrugs via acylation with cinnamate

INVENTOR(S): Gilbert, Carl W.; McGowan, Eleanor B.; Black, Kirby
S.; Harper, Gregory T. P.

PATENT ASSIGNEE(S): Cryolife, Inc., USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083067	A2	20021024	WO 2002-US11330	20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002187992	A1	20021212	US 2002-66306	20020131
PRIORITY APPLN. INFO.:				
			US 2001-284304P	P 20010417
			US 2001-315782P	P 20010828
			US 2002-66306	A 20020131

AB A prodrug compn. contg. a cinnamate moiety and a biol. active mol. moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety's elec. properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biol. active mol. moiety and the cinnamic acid backbone. The biol. active mol. can be any biol. active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, camptothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug compn. can be modified to add a carrier moiety on the prodrug compn. for targeting or to facilitate uptake of the drug. The prodrug compns. can be activated with an energy source to release the drug at the desired site. Representative energy sources can be in the form of elec. force, ultrasound, light or radiation of a radioactive material which can be administered either externally or internally.


IT 473440-37-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of prodrugs via acylation with cinnamate for drug release by hydrolysis or activation by energy source)

RN 473440-37-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethyl
lamino]-2-hydroxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)



IT 473440-38-9P 473440-39-0P 473440-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of prodrugs via acylation with cinnamate for drug release by hydrolysis or activation by energy source)

RN 473440-38-9 CAPLUS


CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-[[3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B







RN 473440-39-0 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[3-[4-[(2-aminoethyl)ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]-.beta.-(benzoylamino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.








RN 473440-43-6 CAPLUS


CN 2-Propenoic acid, 3-[4-[[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl-, 2-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.





Absolute stereochemistry.
Double bond geometry unknown.




RN 473440-44-7 CAPLUS


CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



IT 473440-33-4 473440-34-5D, conjugates with monoclonal

antibodies 473440-35-6 473440-35-6D, conjugates with
monoclonal antibodies


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of prodrugs via acylation with cinnamate for drug release by
hydrolysis or activation by energy source)

RN 473440-33-4 CAPLUS


CN Benzenepropanoic acid, .beta.- (benzoylamino) -.alpha.- [[3- [4- [[2- [[6- [[3-
(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl) -1-oxopropyl] amino] -1-
oxohexyl] amino] ethyl] ethylamino] -2-hydroxyphenyl] -2-methyl-1-oxo-2-
propenyl] oxy] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -6,12b-bis (acetyloxy) -
12- (benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-
dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca [3,4] benz [1,2-b] oxet-9-yl ester, (.alpha.R,.beta.S) - (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 473440-34-5 CAPLUS

CN Benzenepropanoic acid, .beta.- (benzoylamino) -.alpha.- [[3- [4- [[2- [[6- [[3-
(2,5-dioxo-1-pyrrolidinyl) -1-oxopropyl] amino] -1-
oxohexyl] amino] ethyl] ethylamino] -2-hydroxyphenyl] -2-methyl-1-oxo-2-
propenyl] oxy] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -6,12b-bis (acetyloxy) -
12- (benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-


dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 473440-35-6 CAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[3-[[2-[[4-[3-[(1R,2S)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-(benzoylamino)-2-phenylethoxy]-2-methyl-1-oxo-1-propenyl]-3-hydroxyphenyl]ethylamino]ethylamino]-3-oxopropyl]-.omega.-[2-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethoxy]-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C



RN 473440-35-6 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-[3-[[2-[[4-[3-[(1R,2S)-1-
 [[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-
 4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-
 9-yl]oxy]carbonyl]-2-(benzoylamino)-2-phenylethoxy]-2-methyl-1-oxo-1-
 propenyl]-3-hydroxyphenyl]ethylamino]ethyl]amino]-3-oxopropyl]-.omega.-[2-
 [[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethoxy]-
 (9CI) (CA INDEX NAME)

R: DE, FR, GB, NL
 JP 04311952 A2 19921104 JP 1991-103584 19910410
 US 5266453 A 19931130 US 1992-866517 19920410
 PRIORITY APPLN. INFO.: JP 1991-103584 19910410
 OTHER SOURCE(S): MARPAT 118:244465
 GI



AB Photog. material with improved safelight property contains in .gtoreq.1 hydrophilic colloidal layer .gtoreq.1 filter dye which is irreversibly bleached during processing step. The filter dye comprises I (R1,R2 = H, or a substitutable) group; n0, n1, n2 = 0-1; h = 1-2; R1,R2,R3 = may together form a hydrocarbon or heterocyclic ring; Y1 = CO, CO(NR4), CS, C(N+R5R6), SO, SO2, C(CR7R8), R6CN, or C6CCR9 in [(R1)n1 Y1] when n1 = 1 and in Y1(R3)n2 when n2 = 1 in which R4-R9 = H or a substitutable group, Y1 = CN, NO2 in [(R1)nY1] when n1 = 0 and in Y1(R3)n2 when n2 = 0; x - divalent linkage; D = photog. dye residue; M = amphoteric group.

IT 146844-68-0


RL: USES (Uses)

(photog. material with improved safelight property contg. filter dye of)


RN 146844-68-0 CAPLUS

CN 1-Butanaminium, N-[2-[[4-[3-[[4-[[5-chloro-1,2,3,6-tetrahydro-3-methyl-1-[2-(octyloxy)-2-oxoethyl]-2,6-dioxo-4-pyrimidinyl]oxy]phenyl]amino]-2-cyano-3-oxo-1-propenyl]-3-methoxyphenyl]ethylamino]ethyl]-N,N-dimethyl-4-sulfo-, inner salt (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 1-B



ACCESSION NUMBER: 1993:29821 CAPLUS
 DOCUMENT NUMBER: 118:29821
 TITLE: Photographic material containing quick bleachable dyes
 INVENTOR(S): Kawashima, Yasuhiko; Yamauchi, Reiko; Kagawa, Nobuaki
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04116639	A2	19920417	JP 1990-237765	19900907
PRIORITY APPLN. INFO.: GI			JP 1990-237765	19900907




AB The title photog. material contains a dispersed fine solid powder of a compd. selected from I, II and III [R1,2 = H, (cyclo)alkyl, alkenyl, aryl, heterocyclyl, acyl, sulfonyl; R1 and R2 may form a 5- or 6-membered ring; R3-5 = H, halo, alkyl, CO2H, alkoxycarbonyl, aryloxycarbonyl, amino, carbamoyl, sulfamoyl, NO2, CN, OH, alkoxy, SH, aryl, alkenyl; X1 = COR8, CONR8R9, CO2R8, SO2R8, SOR8, SO2NR8R9; R8,9 = H, (cyclo)alkyl, aryl, heterocyclyl, alkenyl; m = 0-2; Y1 = CN, CONR8R9, CO2R8, SO2R8, SOR8, SO2NR8R9; X2, Y2 = COR8R9, CO2R8, SO2R8, SOR8, SO2NR8R9].

IT 144807-25-0

RL: USES (Uses)
 (bleachable dye, photog. material contg.)

RN 144807-25-0 CAPLUS

CN 2-Propenoic acid, 3-[2-methoxy-4-[methyl[2-[(propylsulfonyl)amino]ethyl]amino]phenyl]-2-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1991:682120 CAPLUS
 DOCUMENT NUMBER: 115:282120
 TITLE: Yellow colorants for sublimation thermal-transfer printing
 INVENTOR(S): Chiba, Junji; Kato, Hiroyuki
 PATENT ASSIGNEE(S): Sankyo Kagaku K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02292371	A2	19901203	JP 1989-112005	19890502

PRIORITY APPLN. INFO.: JP 1989-112005 19890502


GI For diagram(s), see printed CA Issue.

AB The title colorants I [R1-2 = H, (un)substituted alkyl, cycloalkyl, aralkyl, aryl; R1-2 may be bonded with X to form 5- or 6-membered ring; R3-4 = H, halo, cyano, (un)substituted alkyl, cycloalkyl, alkoxy, aryl, aralkyl, acylamino, sulfonylamino, ureido, carbamoyl, sulfamoyl, acyl, amino; A1-2 = electron-withdrawing group; one of A1-2 may be aryl; Z = CH, N; Y = divalent group; X = H or group to form 5- or 6-membered ring with R1-2; m, n = 1, 2] are prepd. Thus, condensation of PhNHBu and Br(CH₂)₅Br in presence of Na₂CO₃ and Vilsmeier formylation of the product gave N,N'-di-n-butyl-N,N'-bis(4-formylphenyl)-1,5-diaminopentane, which was then treated with CH₂(CN)₂ to give 80% N,N'-di-n-butyl-N,N'-bis[4-(2,2-dicyanoethylene)phenyl]-1,5-diaminopentane (II). An ink contg. II 4, ethyl Cellosolve 8, MEK 44, and PhMe 44 parts was applied on a capacitor tissue paper and dried to obtain a thermal-transfer material, which gave high-d. image with bright yellow color.

IT **136029-48-6P**
 RL: PREP (Preparation)
 (prepn. of, yellow dye, for sublimation thermal-transfer printing)

RN 136029-48-6 CAPLUS


CN 2-Propenamide, 3,3'-[1,6-hexanediylbis[(ethylimino)[2-[[[(ethylamino)carbonyl]amino]-4,1-phenylene]]]bis[2-cyano-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1991:618966 CAPLUS
 DOCUMENT NUMBER: 115:218966
 TITLE: Biscyanostyrene dyes for thermal-transfer recording
 INVENTOR(S): Chiba, Junji; Kato, Hiroyuki
 PATENT ASSIGNEE(S): Sankyo Chemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03086591	A2	19910411	JP 1989-223015	19890831
PRIORITY APPLN. INFO.:			JP 1989-223015	19890831

GI




AB A dye for thermal-transfer recording has formula I [R, R1 = H, (substituted) alkyl, cycloalkyl, aralkyl, aryl, they may form a 5- or 6-membered ring together with R5, resp.; R2, R3 = H, halo, CN, (substituted) alkyl, cycloalkyl, alkoxy, aryl, aralkyl, acylamino, sulfonylamino, ureido, carbamoyl, sulfamoyl, acyl, amino; R4 = electron-attracting group; R5 = H, atom(s) required to form a 5-or 6-membered ring together with R or R1 ; Z = divalent group; m, n = 1,2]. A thermal-transfer sheet using I (R = R1 = Bu, R2 = R3 = R5 = H, R4 = CN, Z = (CH2)5] gave clear, high d. magenta images.

IT 136967-50-5

RL: USES (Uses)
 (thermal-transfer recording material using)

RN 136967-50-5 CAPLUS

CN 2-Propenamide, 3,3'-[1,6-hexanediylbis[(ethylimino){2-[[(ethylamino)carbonyl]amino]-4,1-phenylene}]]bis[2,3-dicyano-N-phenyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:57:37 ON 02 DEC 2003)

FILE 'REGISTRY' ENTERED AT 09:57:47 ON 02 DEC 2003

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

L3 13 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:01:00 ON 02 DEC 2003

L4 5 S L3


L5 5 DUP REM L4 (0 DUPLICATES REMOVED)

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 16 sss sam

SAMPLE SEARCH INITIATED 10:16:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 159 TO 721

PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s 16 sss full

FULL SEARCH INITIATED 10:16:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 487 TO ITERATE

100.0% PROCESSED 487 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01


L8 13 SEA SSS FUL L6

=> d scan

L8 13 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN 2-Propenoic acid, 3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl- (9CI)

MF C19 H28 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>


Uploading 306-cinnamate-11.str

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR



G1 O,S,NH

Structure attributes must be viewed using STN Express query preparation.

=> s 19 sss sam

SAMPLE SEARCH INITIATED 10:19:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

```
=> s l9 sss full  
FULL SEARCH INITIATED 10:19:46 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE
```

```
100.0% PROCESSED          0 ITERATIONS          0 ANSWERS  
SEARCH TIME: 00.00.01
```

```
L11          0 SEA SSS FUL L9
```

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:813875 CAPLUS
 DOCUMENT NUMBER: 137:329436
 TITLE: Prodrugs via acylation with cinnamate
 INVENTOR(S): Gilbert, Carl W.; McGowan, Eleanor B.; Black, Kirby
 S.; Harper, Gregory T. P.
 PATENT ASSIGNEE(S): Cryolife, Inc., USA
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083067	A2	20021024	WO 2002-US11330	20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002187992	A1	20021212	US 2002-66306	20020131
PRIORITY APPLN. INFO.:			US 2001-284304P	P 20010417
			US 2001-315782P	P 20010828
			US 2002-66306	A 20020131


AB A prodrug compn. contg. a cinnamate moiety and a biol. active mol. moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety's elec. properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biol. active mol. moiety and the cinnamic acid backbone. The biol. active mol. can be any biol. active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, camptothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug compn. can be modified to add a carrier moiety on the prodrug compn. for targeting or to facilitate uptake of the drug. The prodrug compns. can be activated with an energy source to release the drug at the desired site. Representative energy sources can be in the form of elec. force, ultrasound, light or radiation of a radioactive material which can be administered either externally or internally.


IT 473440-37-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of prodrugs via acylation with cinnamate for drug release by hydrolysis or activation by energy source)

RN 473440-37-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethyl]amino]-2-hydroxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)





IT 473440-38-9P 473440-39-0P 473440-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of prodrugs via acylation with cinnamate for drug release by hydrolysis or activation by energy source)

RN 473440-38-9 CAPLUS


CN Benzenepropanoic acid, .beta.- (benzoylamino) -.alpha.- [[3- [4- [[2- [[(1,1-dimethylethoxy) carbonyl] amino] ethyl] ethylamino] -2-hydroxyphenyl] -2-methyl-1-oxo-2-propenyl] oxy] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -6,12b-bis(acetyloxy) -12- (benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca [3,4] benz [1,2-b] oxet-9-yl ester, (.alpha.R,.beta.S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 473440-39-0 CAPLUS


CN Benzenepropanoic acid, .alpha.-[[3-[4-[(2-aminoethyl)ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]-.beta.-(benzoylamino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A





PAGE 1-B




RN 473440-43-6 CAPLUS


CN 2-Propenoic acid, 3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl-, 2-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 473440-37-8DP, conjugates with polyethylene glycol and cytokine
 473440-41-4P 473440-44-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of prodrugs via acylation with cinnamate for drug release by hydrolysis or activation by energy source)
 RN 473440-37-8 CAPLUS
 CN 2-Propenoic acid, 3-[4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)






RN 473440-41-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[[2-[[[(1,1-dimethylethoxy) carbonyl] amino] ethyl] ethylamino]-2-hydroxyphenyl]-2-methyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.





RN 473440-44-7 CAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[3-[[4-[[2-[[[(1,1-dimethylethoxy) carbonyl] amino] ethyl] ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl] amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


PAGE 1-A






IT 473440-33-4 473440-34-5D, conjugates with monoclonal antibodies 473440-35-6 473440-35-6D, conjugates with monoclonal antibodies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prepn. of prodrugs via acylation with cinnamate for drug release by hydrolysis or activation by energy source)
 RN 473440-33-4 CAPLUS
 CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-[[3-[4-[[2-[[6-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]-1-oxohexyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.







RN 473440-34-5 CAPLUS

CN Benzenepropanoic acid, .beta.- (benzoylamino) - .alpha.- [[3-[4-[[2-[[6-[[3-(2,5-dioxo-1-pyrrolidinyl)-1-oxopropyl]amino]-1-oxohexyl]amino]ethyl]ethylamino]-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.
Double bond geometry unknown.






RN 473440-35-6 CAPLUS



CN Poly(oxy-1,2-ethanediyl), .alpha.-[3-[[2-[[4-[3-[(1R,2S)-1-
 [[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-
 4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-
 9-yl]oxy]carbonyl]-2-(benzoylamino)-2-phenylethoxy]-2-methyl-1-oxo-1-
 propenyl]-3-hydroxyphenyl]ethylamino]ethyl]amino]-3-oxopropyl]-.omega.-[2-
 [[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethoxy]-
 (9CI) (CA INDEX NAME)






RN 473440-35-6 CAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[3-[[2-[[4-[3-[(1R,2S)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-(benzoylamino)-2-phenylethoxy]-2-methyl-1-oxo-1-propenyl]-3-hydroxyphenyl]ethylamino]ethyl]amino]-3-oxopropyl]-.omega.-[2-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethoxy]-(9CI) (CA INDEX NAME)






L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1993:244465 CAPLUS
 DOCUMENT NUMBER: 118:244465
 TITLE: Silver halide photographic light-sensitive material
 INVENTOR(S): Matsushita, Tetunori
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 74 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 508432	A1	19921014	EP 1992-106180	19920409
EP 508432	B1	19980325		
R: DE, FR, GB, NL				
JP 04311952	A2	19921104	JP 1991-103584	19910410
US 5266453	A	19931130	US 1992-866517	19920410
PRIORITY APPLN. INFO.:			JP 1991-103584	19910410
OTHER SOURCE(S):		MARPAT 118:244465		

GI



AB Photog. material with improved safelight property contains in .gtoreq.1 hydrophilic colloidal layer .gtoreq.1 filter dye which is irreversibly bleached during processing step. The filter dye comprises I (R¹, R² = H, or a substitutable) group; n₀, n₁, n₂ = 0-1; h = 1-2; R¹, R², R³ = may together form a hydrocarbon or heterocyclic ring; Y¹ = CO, CO(NR⁴), CS, C(N+R⁵R⁶), SO, SO₂, C(CR⁷R⁸), R⁶CN, or C₆CCR⁹ in [(R¹)_{n₁} Y¹] when n₁ = 1 and in Y¹(R³)_{n₂} when n₂ = 1 in which R⁴-R⁹ = H or a substitutable group, Y¹ = CN, NO₂ in [(R¹)_{n₁} Y¹] when n₁ = 0 and in Y¹(R³)_{n₂} when n₂ = 0; x - divalent linkage; D = photog. dye residue; M = amphoteric group.


IT 146844-68-0

RL: USES (Uses)


(photog. material with improved safelight property contg. filter dye

of)
 RN 146844-68-0 CAPLUS
 CN 1-Butanaminium, N-[2-[[4-[3-[[4-[[5-chloro-1,2,3,6-tetrahydro-3-methyl-1-[2-(octyloxy)-2-oxoethyl]-2,6-dioxo-4-pyrimidinyl]oxy]phenyl]amino]-2-cyano-3-oxo-1-propenyl]-3-methoxyphenyl]ethylamino]ethyl]-N,N-dimethyl-4-sulfo-, inner salt (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 1-B



L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1993:29821 CAPLUS
 DOCUMENT NUMBER: 118:29821
 TITLE: Photographic material containing quick bleachable dyes
 INVENTOR(S): Kawashima, Yasuhiko; Yamauchi, Reiko; Kagawa, Nobuaki
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04116639	A2	19920417	JP 1990-237765	19900907
PRIORITY APPLN. INFO.:			JP 1990-237765	19900907

GI



AB The title photog. material contains a dispersed fine solid powder of a compd. selected from I, II and III [R1,2 = H, (cyclo)alkyl, alkenyl, aryl, heterocyclyl, acyl, sulfonyl; R1 and R2 may form a 5- or 6-membered ring; R3-5 = H, halo, alkyl, CO2H, alkoxy, carbonyl, aryloxy, carbonyl, amino, carbamoyl, sulfamoyl, NO2, CN, OH, alkoxy, SH, aryl, alkenyl; X1 = COR8, CONR8R9, CO2R8, SO2R8, SOR8, SO2NR8R9; R8,9 = H, (cyclo)alkyl, aryl, heterocyclyl, alkenyl; m = 0-2; Y1 = CN, CONR8R9, CO2R8, SOR8, SO2NR8R9; X2, Y2 = COR8R9, CO2R8, SO2R8, SOR8, SO2NR8R9].


IT 144807-25-0

RL: USES (Uses)

(bleachable dye, photog. material contg.)

RN 144807-25-0 CAPLUS

CN 2-Propenoic acid, 3-[2-methoxy-4-[methyl[2-[(propylsulfonyl)amino]ethyl]amino]phenyl]-2-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1991:682120 CAPLUS

DOCUMENT NUMBER: 115:282120

TITLE: Yellow colorants for sublimation thermal-transfer printing

INVENTOR(S): Chiba, Junji; Kato, Hiroyuki

PATENT ASSIGNEE(S): Sankyo Kagaku K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02292371	A2	19901203	JP 1989-112005	19890502
PRIORITY APPLN. INFO.:			JP 1989-112005	19890502


GI For diagram(s), see printed CA Issue.

AB The title colorants I [R1-2 = H, (un)substituted alkyl, cycloalkyl, aralkyl, aryl; R1-2 may be bonded with X to form 5- or 6-membered ring; R3-4 = H, halo, cyano, (un)substituted alkyl, cycloalkyl, alkoxy, aryl, aralkyl, acylamino, sulfonylamino, ureido, carbamoyl, sulfamoyl, acyl, amino; A1-2 = electron-withdrawing group; one of A1-2 may be aryl; Z = CH, N; Y = divalent group; X = H or group to form 5- or 6-membered ring with R1-2; m, n = 1, 2] are prepd. Thus, condensation of PhNHBu and Br(CH₂)₅Br in presence of Na₂CO₃ and Vilsmeier formylation of the product gave N,N'-di-n-butyl-N,N'-bis(4-formylphenyl)-1,5-diaminopentane, which was then treated with CH₂(CN)₂ to give 80% N,N'-di-n-butyl-N,N'-bis[4-(2,2-dicyanoethylene)phenyl]-1,5-diaminopentane (II). An ink contg. II 4, ethyl Cellosolve 8, MEK 44, and PhMe 44 parts was applied on a capacitor tissue paper and dried to obtain a thermal-transfer material, which gave high-d. image with bright yellow color.

IT **136029-48-6P**
 RL: PREP (Preparation)
 (prepn. of, yellow dye, for sublimation thermal-transfer printing)

RN 136029-48-6 CAPLUS

CN 2-Propenamide, 3,3'-[1,6-hexanediylbis[(ethylimino) [2-[[[(ethylamino) carbonyl] amino]-4,1-phenylene]]]bis[2-cyano-N-phenyl- (9CI) (CA INDEX NAME)]



L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1991:618966 CAPLUS

DOCUMENT NUMBER: 115:218966

TITLE: Biscyanostyrene dyes for thermal-transfer recording

INVENTOR(S): Chiba, Junji; Kato, Hiroyuki

PATENT ASSIGNEE(S): Sankyo Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03086591	A2	19910411	JP 1989-223015	19890831
PRIORITY APPLN. INFO.:			JP 1989-223015	19890831

GI




AB A dye for thermal-transfer recording has formula I [R, R1 = H, (substituted) alkyl, cycloalkyl, aralkyl, aryl, they may form a 5- or 6-membered ring together with R5, resp.; R2, R3 = H, halo, CN, (substituted) alkyl, cycloalkyl, alkoxy, aryl, aralkyl, acylamino, sulfonylamino, ureido, carbamoyl, sulfamoyl, acyl, amino; R4 = electron-attracting group; R5 = H, atom(s) required to form a 5-or 6-membered ring together with R or R1 ; Z = divalent group; m, n = 1,2]. A thermal-transfer sheet using I (R = R1 = Bu, R2 = R3 = R5 = H, R4 = CN, Z = (CH2)5] gave clear, high d. magenta images.

IT 136967-50-5

RL: USES (Uses)
(thermal-transfer recording material using)

RN 136967-50-5 CAPLUS

CN 2-Propenamide, 3,3'-[1,6-hexanediylbis[(ethylimino)[2-[[[(ethylamino)carbonyl]amino]-4,1-phenylene]]]bis[2,3-dicyano-N-phenyl-(9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:57:37 ON 02 DEC 2003)

FILE 'REGISTRY' ENTERED AT 09:57:47 ON 02 DEC 2003

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

L3 13 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:01:00 ON 02 DEC 2003

L4 5 S L3

L5 5 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 10:13:34 ON 02 DEC 2003

L6 STRUCTURE UPLOADED

L7 0 S L6 SSS SAM

L8 13 S L6 SSS FULL

L9 STRUCTURE UPLOADED

L10 0 S L9 SSS SAM

L11 0 S L9 SSS FULL


FILE 'CAPLUS, MEDLINE' ENTERED AT 10:22:01 ON 02 DEC 2003

L12 5 S L8

FILE 'REGISTRY' ENTERED AT 10:22:21 ON 02 DEC 2003
L13 13 DUP REM L8 (0 DUPLICATES REMOVED)

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:22:40 ON 02 DEC 2003
L14 5 DUP REM L12 (0 DUPLICATES REMOVED)
L15 0 S L12 NOT L4

d l16
L16 HAS NO ANSWERS
L16 STR



G1 O, S, NH

Structure attributes must be viewed using STN Express query preparation.

=> s l16 sss sam
SAMPLE SEARCH INITIATED 10:31:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L17 0 SEA SSS SAM L16

=> s l16 sss full
FULL SEARCH INITIATED 10:31:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L18 0 SEA SSS FUL L16

d his

(FILE 'HOME' ENTERED AT 09:57:37 ON 02 DEC 2003)

FILE 'REGISTRY' ENTERED AT 09:57:47 ON 02 DEC 2003

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 13 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:01:00 ON 02 DEC 2003

L4 5 S L3
L5 5 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 10:13:34 ON 02 DEC 2003

L6 STRUCTURE UPLOADED
L7 0 S L6 SSS SAM
L8 13 S L6 SSS FULL
L9 STRUCTURE UPLOADED
L10 0 S L9 SSS SAM
L11 0 S L9 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:22:01 ON 02 DEC 2003

L12 5 S L8

FILE 'REGISTRY' ENTERED AT 10:22:21 ON 02 DEC 2003

L13 13 DUP REM L8 (0 DUPLICATES REMOVED)

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:22:40 ON 02 DEC 2003

L14 5 DUP REM L12 (0 DUPLICATES REMOVED)
L15 0 S L12 NOT L4

FILE 'REGISTRY' ENTERED AT 10:31:22 ON 02 DEC 2003

L16 STRUCTURE UPLOADED
L17 0 S L16 SSS SAM
L18 0 S L16 SSS FULL